Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04050358
Other study ID # Basis-HIIT
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date February 2023
Est. completion date May 2023

Study information

Verified date February 2023
Source Elysium Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, randomized, placebo-controlled pilot study to evaluate the effects of high intensity interval training (HIIT) and daily administration of BasisTM for 3 weeks, in 18-35 year old males. The study will consist of a screening visit, baseline visit, followed by treatment and HIIT phase (3 weeks) and a post-supplementation, follow-up visit (this will occur 48 h (or more) after the final HIIT session). Following the screening phase, subjects who meet entry criteria will be randomly assigned to 1 of 2 treatment groups: recommended dose of BasisTM (250 mg Nicotinamide Riboside and 50 mg Pterostilbene) per day or matching-placebo in a 1:1 ratio.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2023
Est. primary completion date April 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - 18 to 35 year old males - Body mass index between 18.5-30 kg.m-2 - Ability to give informed consent - Recreationally active (defined in the present study as exercising once a week or more). Exclusion Criteria: - Those regularly conducting HIIT or highly trained in endurance events (e.g. triathlete) - Currently taking supplements known to affect metabolism (e.g. ibuprofen, stimulants, vitamins, NR) - Taking prescribed medication - Consuming a vegan diet - Consuming a high fat, low carbohydrate diet - Habitual consumption of protein and/or dairy supplements (e.g. whey protein) - Smokers

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
NRPT
Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
Placebo oral capsule
Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks

Locations

Country Name City State
United Kingdom University of Exeter Exeter

Sponsors (2)

Lead Sponsor Collaborator
Elysium Health University of Exeter

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mitochondrial function Measured via high-resolution respirometry using the Oroboros Oxygraph 3 weeks
Secondary Exercise Capacity To measure maximal endurance capacity measured via VO2max 3 weeks
Secondary Muscle strength To measure maximal voluntary contraction using a force transducer strength chair 3 weeks
Secondary Muscle power Determine the effects of HIIT with and without NRPT supplementation on muscle power producing capabilities measured by the 30 second Wingate test 3 weeks
Secondary Mitochondrial proteins To determine whether HIIT with NRPT supplementation improves mitochondrial function more so than HIIT alone, using Western blotting 3 weeks
Secondary Body Mass To determine the effects of HIIT with and without NRPT supplementation on body composition by measuring body mass using a bioelectrical impedance analysis scale 3 weeks
Secondary Percent Body Fat To determine the effects of HIIT with and without NRPT supplementation on body composition by measuring percent body fat using a bioelectrical impedance analysis scale 3 weeks
Secondary Recovery via POMS To determine the effects of HIIT with and without NRPT supplementation on recovery via profile of mood states (POMS) 3 weeks
Secondary Recovery via RESTQ To determine the effects of HIIT with and without NRPT supplementation on recovery via recovery stress (RESTQ) questionnaire 3 weeks
Secondary Physical activity levels using FitBit To characterize volunteer's habitual physical activity levels. 3 weeks
Secondary Height Measure height using a stadiometer, to characterize demographics of recruited volunteers the recruited volunteers 3 weeks
Secondary Blood pressure Measure blood pressure using Dinamap Pro monitor to characterize demographics of recruited volunteers the recruited volunteers 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1